BIO logo

  • June 3-6, 2024
  • San Diego Convention Center, California

Sessions

At BIO 2024, where issues & insights converge, you can access more than 100 sessions across 18 focus areas with discussions from leading biotechnology companies, investors, service providers, government officials, regulators, and patient advocates committed to ground-breaking therapies and innovation.

Be sure to register for a Premier Access or General Access pass in order to attend these sessions.

Follow this schedule for updates as new speakers and topics become available.

Loading
Search Filters
  • Date
  • Session Type
  • Focus Area
We're sorry, but we couldn't find any results that match your search criteria. Please try again with different keywords or filters.
Loading
9:00 AM – 12:00 PM
(PST)
  1. Partnering with the U.S. Government to Achieve Our National Security Mission
    Breakout Session
    • Infectious Disease and Vaccines
    28ABCDE
12:00 PM – 1:00 PM
(PST)
  1. How to Build a Successful and Competitive Biopharma Ecosystem in Southeast Asia
    Breakout Session
    • Asia-Pacific Opportunities
    30ABC
    Mai Zymaris
    Mai Zymaris, Counsel - Baker McKenzie
    Phong Tran
    Mr. Phong Tran, CEO - BOUND Therapeutics and siRnaMed Therapeutics
    John Mattison
    John Mattison, Operating Partner and Chief Medical Information Officer - Arsenal Capital Partners
    Anh Hoang-Lindsay
    Anh Hoang-Lindsay, CEO - Jana Care
    Alex Wang
    Alex Wang, Head of Business Development, US & China - Zuellig Pharma
1:45 PM – 2:45 PM
(PST)
  1. A Discussion on Increasing Healthspan
    Breakout Session
    • Next Generation Biotherapeutics
    23BC
    Hilary Brueck
    Hilary Brueck, Journalist - Business Insider
    Dan Oliver
    Mr. Dan Oliver, CEO & Co-Founder - Rejuvenate Bio
    Katharine Grabek
    Katharine Grabek, Co-Founder and CSO - Fauna Bio
    Jake Becraft
    Jake Becraft, CEO & Founder - Strand Therapeutics
    Alex Aravanis
    Alex Aravanis, CEO - Moonwalk Biosciences
    Jennifer Bergheiser
    Jennifer Bergheiser, Chief Business Officer - eGenesis
  2. A Licensing Deal for All Seasons
    Breakout Session
    • Business Development and Finance
    29AB
    Jonathan Grinstein
    Jonathan Grinstein, Senior Editor - Genetic Engineering & Biotechnology News
    Uneek Mehra
    Uneek Mehra, CHIEF FINANCIAL & BUSINESS OFFICER - 4DMT
    Kunal Patel
    Mr. Kunal Patel, VP of Business Development - Synthekine
    Gavin Samuels
    Dr. Gavin Samuels, Chief Business Officer - CinRx Pharma
    Lesley Stolz
    Lesley Stolz, Vice President - Johnson & Johnson Innovation
    Richard Wilson
    Richard Wilson, Senior VP, Primary Focus Lead of Genetic Regulation - Astellas Gene Therapies
  3. All Money is NOT Created Equal: The Differences between Angel, Venture and Strategic Capital in the Biotech Funding Ecosystem
    Breakout Session
    • Business Development and Finance
    32AB
    Yaniv Sneor
    Mr. Yaniv Sneor, Founder & Managing Director - Mid Atlantic Bio Angels
    Jonathan McClain
    Jonathan McClain, Executive Director, Eli Lilly Catalyze team - Eli Lilly
    Max Farina
    Dr. Max Farina, Senior Associate - 5AM Ventures
  4. Alternative Funding Programs: Protecting Patients in an Ever-Changing Healthcare Landscape
    Breakout Session
    • Patient Advocacy
    26A
    Ashira Vantrees
    Ashira Vantrees, Counsel - Aimed Alliance
    Kollet Koulianos
    Kollet Koulianos, Vice President Payer Relations - National Hemophilia Foundation
    Kim Czubaruk
    Kim Czubaruk, Associate Vice President of Policy - Cancer Care
    Richard Meyers
    Richard Meyers, Head, State Policy - Bristol Myers Squibb
    Dani Peters
    Dani Peters, President - Magnet Strategy Group
  5. Building Capacities in the Industry for Secondary Uses of Health Data: The EHDS Framework
    Breakout Session
    • AI and Digital Health
    24BC
    Montse Daban
    Dr. Montse Daban, Director of Strategic Foresight and International Relations and President - Biocat and The Council of European BioRegions
    Jean Marc Bourez
    Dr. Jean Marc Bourez, CEO - EIT Heatlth
    Elina Drakvik
    Ms. Elina Drakvik, Senior lead, Health Data 2030 - Sitra
    Christopher Morton
    Christopher Morton, Business Executive and Ceo - ELEM Biotech
    Aenor Sawyer
    Aenor Sawyer, Director UC Space Health - University of San Francisco
    Brad Ship
    Brad Ship, Partner - Alira Health
  6. Empowering Real World Patient-Centric Digital Health in Asia with Digital Apps
    Breakout Session
    • Asia-Pacific Opportunities
    30ABC
    Tsu-Hui Liu
    Dr. Tsu-Hui Liu, Director of Biotechnology, Health, Medicine and Agriculture Division, - Office of Science and Technology Policy, National Science and Technology Council (NSTC)
    Jared Josleyn
    Dr. Jared Josleyn, Global Head of Digital Healthcare - Sanofi
    Chu-Yie Deng
    Mr. Chu-Yie Deng, co-founder and CEO - Health2Sync
    Allen Lien
    Dr. Allen Lien, Chairman & CEO - Acer Medical Inc.
  7. Super Session
    Fireside Chat with Nauman Shah, Global Head of Business Development, Johnson & Johnson Innovative Medicine
    Super Session
    • Business Development and Finance
    28ABCDE
    Sponsored by:
    johnson and johnson
    Nauman Shah
    Nauman Shah, Global Head of Business Development - Johnson & Johnson Innovative Medicine
  8. Lessons from the Oregon Trail: Pioneering Gene Therapy in the Real World
    Breakout Session
    • Cell and Gene Therapy and Genome Editing
    31AB
    Tom Klima
    Tom Klima, Chief Operating and Commercial Officer - bluebird bio
    Joe Garrity
    Mr. Joe Garrity, Senior Director, Head of Autologous Cell Therapy - Lonza
    Tim Olson
    Tim Olson, Medical Director, Blood and Marrow Transplant Program - Children's Hospital of Philadelphia
    Michelle Campbell
    Michelle Campbell, Caregiver - N/A
    Kirk Davis
    Kirk Davis, Clinical Business Program Manager, Gene Therapy - Cigna
  9. The Cross-Border Applicability of RWD in Decision-Making
    Breakout Session
    • Regulatory Innovation
    31C
    Rachel Ehlers
    Rachel Ehlers, Partner - Baker McKenzie
    Michele Colucci
    Michele Colucci, Founder & Managing Partner - DigitalDx Ventures
    Michelle Wong
    Michelle Wong, Head of Operations - Octant
    Jonathan Fairtlough
    Jonathan Fairtlough, Principal - KPMG
    Virginia Sanzone
    Virginia Sanzone, General Counsel - ICU Medical
  10. The Time is Now: Global Perspectives on Preparing for Public Health Emergencies
    Breakout Session
    • Infectious Disease and Vaccines
    29C
    Sponsored by:
    Emergent logo
3:00 PM – 4:00 PM
(PST)
  1. A New Era for Access and Affordability: Considerations for Patients and Manufacturers in a Post-IRA World
    Breakout Session
    • Patient Advocacy
    26A
    Mark Gooding
    Mark Gooding, Managing Director - Avalere
    Anna Hyde
    Anna Hyde, Vice President of Advocacy and Access - Arthritis Foundation
  2. A Perspective from the Trenches: Challenges of Budgeting for Gene Therapies, Innovative Payment Systems That Work for Medicaid Departments and Patients, and What the States Need from CMS
    Breakout Session
    • Cell and Gene Therapy and Genome Editing
    31AB
    Thomas Barker
    Thomas Barker, Partner - Foley Hoag LLP
    Scott McGoohan
    Scott McGoohan, Executive Director, Policy and Alliance Development - Vertex Pharmaceuticals
    Jay Newman
    Mr. Jay Newman, SVP, Commercial Development, Pricing & Reimbursement - Spark Therapeutics, Inc.
  3. AI and Regulatory Innovation in Healthcare: Shaping the Future
    Breakout Session
    • Regulatory Innovation
    31C
    Paul Howard
    Paul Howard, Senior Director of Public Policy - Amicus Therapeutics
    Lina Nilsson
    Lina Nilsson, VP of Product - Recursion
    Meredith Brown-Tuttle
    Meredith Brown-Tuttle, Chief Regulatory Strategist - Regulatorium
    Shlomo Klapper
    Shlomo Klapper, COO - Weave
  4. An Insider Look at Top Deals from 2023
    Breakout Session
    • Business Development and Finance
    29AB
    Carin Canale-Theakston
    Carin Canale-Theakston, CEO - Evoke Canale
    Mark McKenna
    Mark McKenna, CEO - Mirador Therapeutics
    Enoch Kariuki
    Enoch Kariuki, President - Endeavor Biomedicines
  5. Biotech Beyond Borders: Emerging Stronger from a Complex Macroenvironment
    Breakout Session
    • Business Development and Finance
    32AB
    Arda Ural
    Mr. Arda Ural, Americas Leader for Life Sciences and Healthcare - EY (Ernst & Young)
    Chris Garabedian
    Mr. Chris Garabedian, VC Portfolio Manager - Perceptive Advisors
    Barbara Ryan
    Ms. Barbara Ryan, Board Member - Indivior, Mink, OccuTerra, Invo, SafeCor Pharmaceutical Companies
    Brian Bronk
    Brian Bronk, Global Head of Business Development, Neurology, Rare Diseases & Technology Platforms - Sanofi
  6. Emerging Technologies Fostering Biotech Innovation Globally
    Breakout Session
    • Emerging Opportunities in Global Markets
    26B
    Falk Ehmann
    Dr. Falk Ehmann, Head of Innovation and Development Accelerator (IDeA) - European Medicines Agency (EMA)
    Blythe Adamson
    Dr. Blythe Adamson, Senior Principal Scientist, Head of Outcomes Research - Flatiron Health
    Lesley Maloney
    Lesley Maloney, Global Regulatory Policy Lead for Digital Health - Genentech, Inc., A Member of the Roche Group
    Carmen Laplaza-Santos
    Carmen Laplaza-Santos, Head of Unit, Directorate-General for Research and Innovation - European Commission
    Robert Schroeder
    Robert Schroeder, Head of External Communications - European Innovation Council and SMEs Executive Agency (EISMEA)
    Mahesh Yadav
    Mahesh Yadav, Distinguished Scientist - Genentech
  7. Fireside Chat
    Fireside Chat with Stephen Quake, Head of Science, Chan Zuckerberg Initiative
    Fireside Chat
    • Next Generation Biotherapeutics
    25ABC
    Steve Quake
    Steve Quake, Head of Science - Chan Zuckerberg Initiative
  8. Forging New Pathways to Reimbursement for Digital Therapeutics: Considerations for Payer Coverage
    Breakout Session
    • AI and Digital Health
    24BC
    Brigit Kyei-Baffour
    Brigit Kyei-Baffour, Principal - Avalere
    Mona Chitre
    Mona Chitre
    Jon Campbell
    Jon Campbell
  9. Global Policy Perspectives on the Next Generation of Rare Disease Medicines
    Breakout Session
    • Orphan and Rare Disease
    28ABCDE
    Sponsored by:

    merck logo

    Jannie Oosthuizen
    Jannie Oosthuizen, President - Merck
  10. Let’s Go STEDI: Moving Beyond QALY’s to Understand the True Value of Antimicrobials and Vaccines
    Breakout Session
    • Infectious Disease and Vaccines
    29C
    Ted Buckley
    Dr. Ted Buckley, Vice President, Government Affairs - Shionogi
    John Rex
    Dr. John Rex, Chief Medical Officer - F2G
    Scott Johnson
    Dr. Scott Johnson, CEO/Founder - Medicus Economics
    Ella Balasa
    Ms. Ella Balasa, Patient Expert - Balasa Consulting
  11. Longevity Therapeutics Enter Biopharma Mainstream
    Breakout Session
    • Next Generation Biotherapeutics
    23BC
    Brian Gormley
    Brian Gormley, Reporter - Wall Street Journal
    Marco Quarta
    Dr. Marco Quarta, Founder and CEO - Rubedo Life Sciences
    Robert Gould
    Robert Gould, Operating Partner - Khosla Ventures
    Simone Fantaccini
    Dr. Simone Fantaccini, Chief Scientific Officer & Head of Medical Affairs - Novartis
    Cristina Ghenoiu
    Cristina Ghenoiu, Investor - Mubadala Capital
    Hanadie Yousef
    Hanadie Yousef, Chief Executive Officer and Co-Founder - Juvena Therapeutics
  12. Patients Wait Less: Streamlining Regulatory Pathways for Cell/Gene Therapies in Asia-Pacific Region
    Breakout Session
    • Asia-Pacific Opportunities
    30ABC
    Pi-Sheng Wang
    Dr. Pi-Sheng Wang, Deputy Minister - Ministry of Health and Welfare
    Akira Sakurai
    Akira Sakurai, Deputy Reviewer Director - Pharmaceuticals and Medical Devices Agency
    Yueh-Ping Liu
    Dr. Yueh-Ping Liu, Director-General - Department of Medical Affairs, Ministry of Health and Welfare
    Maggie Ho
    Dr. Maggie Ho, General Manager, Asian Business & CMC Regulatory Development - Amarex Clinical Research, LLC
    Joseph Damond
    Mr. Joseph Damond, Chair of Health Policy - Edelman Global Advisory
4:15 PM – 5:15 PM
(PST)
  1. Agile Biologics Manufacturing Strategy to Meet Market Demand
    Breakout Session
    • Business Development and Finance
    30DE
    Sponsored by:
    thermofisher scientific
  2. Altering the Regulatory Ecosystem for Pediatric Clinical Programs: Intended and Unintended Consequences
    Breakout Session
    • Regulatory Innovation
    31C
    Catherine Lee
    Dr. Catherine Lee, Associate Director, Global Regulatory Policy and Intelligence - Johnson & Johnson
    Laurie Conklin
    Dr. Laurie Conklin, Senior Director, Pediatric Development - Johnson & Johnson
    Dionna Green
    Dr. Dionna Green, Director, Office of Pediatric Therapeutics - FDA
    Thomas Miller
    Dr. Thomas Miller, Global Head, Acute, Chronic & Pediatric Disease Nucleus - Bayer
  3. Avoid the Cycle of “Panic and Neglect": How Ongoing Commitment to Innovative Partnerships Futureproofs Against the Next Pandemic
    Breakout Session
    • Infectious Disease and Vaccines
    29C
    Paul Friedrichs
    Paul Friedrichs, Director - Office of Pandemic Preparedness and Response Policy (OPPR)
    Georges Benjamin
    Dr. Georges Benjamin, Executive Director - American Public Health Association
    Robert Walker
    Dr. Robert Walker, Senior Vice President and Chief Medical Officer - Novavax, Inc.
    Laurent Muschel
    Mr. Laurent Muschel, Director - Deputy Head - European Commission, Health Emergency Preparedness and Response Authority (HERA)
    Emma Wheatley
    Ms. Emma Wheatley, Director, Access and Private Partnerships - CEPI
  4. Creative Structures for Keeping Innovation Alive After the Deal
    Breakout Session
    • Business Development and Finance
    29AB
    Oren Livne
    Mr. Oren Livne, Partner - Baker McKenzie
    Gavin Liu
    Gavin Liu, Senior Director, Legal Strategic Transactions - Astellas
    Paul van der Horst
    Dr. Paul van der Horst, Chief Business Officer - AgomAb Therapeutics
    Deepa Talpade
    Deepa Talpade, Vice President, Head BD&L and Alliance Mgmt., Oncology - Bayer
  5. Fireside Chat
    Fireside Chat with Matt Gline, CEO, Roivant Sciences
    Fireside Chat
    • Business Development and Finance
    25ABC
    Michelle Davis
    Michelle Davis, M&A Reporter - Bloomberg News
    Matt Gline
    Matt Gline, Chief Executive Officer - Roivant Sciences
  6. From Patients to Partners: Patient Advocacy and Biotech Collaborate to Accelerate Innovation
    Breakout Session
    • Patient Advocacy
    26A
    Anthony Mancini
    Anthony Mancini, EVP & Chief Operating Officer - Genmab
    Meghan Gutierrez
    Meghan Gutierrez, CEO - Lymphoma Research Foundation
    Portia Badham
    Portia Badham
  7. Gun Violence Prevention: A Case Study in Passing Meaningful Policies in a Hyper Partisan Era
    Special Program
    • Regulatory Innovation
    28ABCDE
    Josh Horwitz
    Josh Horwitz, Co-director - Johns Hopkins Center for Gun Violence Solutions
    Angus McQuilken
    Angus McQuilken, Life Sciences Industry Relationship Executive - McDermott Will & Emery
    Jen Pauliukonis
    Jen Pauliukonis, Director of Policy and Programming - Johns Hopkins Center for Gun Violence Solutions
    Traci Murphy
    Traci Murphy, Executive Director - Coalition for a Safer Delaware
  8. Innovation Passport: Emerging Opportunities for Company Growth in Global Markets
    Breakout Session
    • Business Development and Finance
    32AB
    Susie Harborth
    Ms. Susie Harborth, Chief Business Officer - Breakthrough Properties
    Bernard Parker
    Bernard Parker, Chief Business Officer - Shanghai Pharma Biotherapeutics USA, Inc.
    Avi Spier
    Dr. Avi Spier, Executive Director Business Development and Licensing - Novartis
    Kristen Albright
    Dr. Kristen Albright, CEO - Prokarium
    Wen Qi Ho
    Wen Qi Ho, Therapeutics Lead - ClavystBio
  9. Investors' Perspectives: Digital Health Trends and Investment Thesis in 2024 and Beyond
    Breakout Session
    • AI and Digital Health
    24BC
    Josh Seidenfeld
    Josh Seidenfeld, Partner and Chair, Digital Health - Cooley LLP
  10. Quality Standards for Final Preparation of CGT Product at Point of Care (POC)
    Breakout Session
    • Cell and Gene Therapy and Genome Editing
    31AB
    Maria Amaya
    Dr. Maria Amaya, Lead External Advocacy, Quality Policy and Advocacy - Genentech, A member of the Roche Group
    Lesbeth Rodriguez
    Dr. Lesbeth Rodriguez, Director, Regulatory Affairs, Policy and Innovation - Bayer
    Maria Sørensen
    Dr. Maria Sørensen, Specialist, RA CMC Lead - Novo Nordisk
    Steffen Thirstrup
    Dr. Steffen Thirstrup, Chief Medical Officer - European Medicines Agency (EMA)
  11. Unlocking Biotech Growth: Hong Kong as the Gateway to Global Markets
    Breakout Session
    • Asia-Pacific Opportunities
    30ABC
  12. Unlocking Success to Biotech Global Expansion: A Stepwise Game Plan for International Launch
    Breakout Session
    • Emerging Opportunities in Global Markets
    26B
    Eduardo Schur
    Eduardo Schur, US Health Sciences & Wellness Commercial Strategy and R&D Lead - EY
  13. Use of AI in mRNA: The New Revolution?
    Breakout Session
    • Next Generation Biotherapeutics
    23BC
    Andy French
    Andy French, Director, Data & AI - CGI
    Mathieu Blanchette
    Dr. Mathieu Blanchette, Director - McGill University
    Christian Barrow
    Christian Barrow, Executive Director - J.P. Morgan
    Petrina Kamya
    Dr. Petrina Kamya, Vice President and Global Head of AI Platforms, Insilico Medicine - President, Insilico Medicine Canada
    Andrew Giessel
    Andrew Giessel, Executive Director - Moderna
11:00 AM – 12:00 PM
(PST)
  1. AI's Trial by Fire: Experimental Validation in Drug Discovery
    Breakout Session
    • AI and Digital Health
    24BC
    Nitya Sridhar
    Nitya Sridhar, Senior Forecasting Associate - Amgen
    Martin Akerman
    Dr. Martin Akerman, Co-founder and CTO - Envisagenics
    Alex Zhavoronkov
    Alex Zhavoronkov, CEO - Insilico
    Michael Bembem
    Michael Bembem, Director, Data Science and External Innovation - Johnson & Johnson
    Etai Jacob
    Etai Jacob, Senior Director, Head of Data Science and AI, Early Oncology - AstraZeneca
    Stacie Calad Thomson
    Stacie Calad Thomson, Chief Strategy Officer & Head of Drug Discovery - BioSymetrics
  2. Avoiding Commercialization Pitfalls for Cell and Gene Therapies
    Breakout Session
    • Cell and Gene Therapy and Genome Editing
    30ABC
  3. Brick-by-Brick: Building a Biotech from Foundation Up with Venture Investor Company Formation
    Breakout Session
    • Business Development and Finance
    26B
    Allison DeAngelis
    Ms. Allison DeAngelis, Reporter - STAT News
    Ann Lee-Karlon
    Ann Lee-Karlon, Chief Executive Officer and President - EpiBiologics
    Jay Parrish
    Dr. Jay Parrish, Chairman and Chief Executive Officer - Pretzel Therapeutics
    Amy Liu
    Mrs. Amy Liu, Investor - Mubadala Capital
    Mitchell Mutz
    Mitchell Mutz, Entrepreneur Partner - Vivo Capital
  4. Build Your Product Pipeline with Non-Dilutive Federal Resources
    Breakout Session
    • Business Development and Finance
    29AB
    Stephanie Fertig
    Ms. Stephanie Fertig, Director, NIH Small Business Program - National Institutes of Health (NIH)
    Elaine Haynes
    Ms. Elaine Haynes, President and CEO - KaloCyte, Inc.
    Julius Korley
    Julius Korley, Associate Vice President, Office of Economic Innovation and Partnerships - University of Delaware
    Meghan Wood
    Ms. Meghan Wood, Managing Director - New York Blood Center Ventures
  5. Building a Bioscience Economy Through Supportive State Legislation: A Discussion with State Legislators from California, Massachusetts, and the Midwest
    Special Program
    • Regulatory Innovation
    29C
  6. FDA Townhall
    Special Program 25ABC
    Patrizia Cavazzoni
    Dr. Patrizia Cavazzoni, Director, Center for Drug Evaluation and Research - FDA
  7. In and Out of This World: Partnering with Federal Labs
    Breakout Session
    • Business Development and Finance
    32AB
    Vladimir Popov
    Vladimir Popov, Chief Innovation Officer - Frederick National Laboratory for Cancer Research
    Edward Diehl
    Edward Diehl, Commercialization Officer - U.S. Army Medical Research and Development Command
    Tara Kirby
    Tara Kirby, Director of the Office of Technology Transfer - National Institute of Health
    Michael Roberts
    Dr. Michael Roberts, Chief Scientific Officer - International Space Station National Laboratory
    Gillian Fenton
    Gillian Fenton, Vaccines Legal Operations - GSK
    Lisa Thomas Read
    Dr. Lisa Thomas Read, Vice President, Research and Development - Amivas (US), LLC
  8. New Pain Therapeutics: Strategies for Innovation, Investment, and Collaboration
    Breakout Session
    • Next Generation Biotherapeutics
    23BC
    Hernan Bazan
    Dr. Hernan Bazan, CEO & Co-Founder - South Rampart Pharma, Inc.
    Emily Caporello
    Dr. Emily Caporello, Program Director, Division of Translational Research - NINDS, NIH
    Paige Cramer Lacatena
    Paige Cramer Lacatena, Director Business Development and Licensing, HQ Neurology - Merck
    Ana Moreno
    Ana Moreno, CEO and Founder - Navega Therapeutics
    Paul Mieyal
    Dr. Paul Mieyal, Managing Director - Outcome Capital, LLC
  9. Strengthening of the Clinical Trials Environment in Europe Under the Accelerating Clinical Trials (ACT EU) Initiative
    Breakout Session
    • Clinical Trials Innovations
    31C
    Laura Pioppo
    Ms. Laura Pioppo, ACT EU Programme manager - European Medicines Agency (EMA)
    Claire Skentelbery
    Dr. Claire Skentelbery, Director General - EuropaBio
  10. Targeting the Brain: How Biotech is Uncovering the Biology of Brain Disease for Precision Neurotherapeutics
    Breakout Session
    • Brain Health
    26A
    Alaa Halawa
    Alaa Halawa, Executive Director and Head of Healthcare, US Ventures - Mubadala Capital
    Carol Suh
    Carol Suh, Co-founder & Chief Operating Officer - Neumora
    Joanne Taylor
    Joanne Taylor, Senior Vice President, Research - Gain Therapeutics
    Richard Shea
    Mr. Richard Shea, CEO - Basking Biosciences
    Craig Thompson
    Craig Thompson, CEO - Cerevance
1:45 PM – 2:30 PM
(PST)
  1. The State of Emerging Biotechs: Investment, Deal, and Pipeline Trends
    Special Program
    • Business Development and Finance
    32AB
    David Thomas
    David Thomas, Senior Vice President, Industry Research - Biotechnology Innovation Organization (BIO)
1:30 PM – 2:45 PM
(PST)
  1. Accelerating the Globalization of Cell and Gene Therapies
    Breakout Session
    • Cell and Gene Therapy and Genome Editing
    31AB
    Jennifer Rabin
    Jennifer Rabin, Specialist Leader - Deloitte Consulting LLP
    Dirk DeNaeyer
    Dirk DeNaeyer, Head of Development Operations - Galapagos
    Sumant Ramachandra
    Sumant Ramachandra, CEO - Impact Bio
    Shahrukh Hashmi
    Dr. Shahrukh Hashmi, Faculty - Mayo Clinic
  2. AI/ML is Transforming R&D and Business
    Breakout Session
    • AI and Digital Health
    24BC
    Maude Tessier
    Dr. Maude Tessier, Chief Business Officer - Seismic Therapeutic
    Karen Akinsanya
    Karen Akinsanya, President, R&D - Therapeutics - Schrodinger, Inc.
    Gary Glick
    Gary Glick, Founder and CEO - Odyssey Therapeutics
    Jiye Shi
    Jiye Shi, Vice President - Eli Lilly
  3. Creative Claiming for Platforms & Products: Designing an IP Strategy to Go Global
    Breakout Session
    • Intellectual Property
    26B
    Tanis Keirstead
    Dr. Tanis Keirstead, Partner - Mewburn Ellis
    Robin Silva
    Ms. Robin Silva, Vice President of Intellectual Property - Xencor, Inc.
    Malathi Lakshmikumaran
    Dr. Malathi Lakshmikumaran, Executive Director and Practice Head - Lakshmikumaran & Sridharan
    Yoon Suk SHIN
    Ms. Yoon Suk SHIN, Senior Partner/Patent Attorney - Lee International IP & Law
    Amy Feng
    Ms. Amy Feng, Managing Partner - Wu, Feng & Zhang
  4. Fireside Chat
    Fireside Chat with Robert A. Bradway, Chairman and Chief Executive Officer, Amgen
    Fireside Chat
    • Business Development and Finance
    25ABC
    Robert Bradway
    Robert Bradway, Chief Executive Officer and Chairman - Amgen
  5. Joining Forces to Accelerate Innovation in Oncology
    Breakout Session
    • Oncology
    30ABC
    Sponsored by:
    Genentech logo
    Visali Ramanathan
    Visali Ramanathan, Executive Director - Genentech
  6. NIH Support for Minority Health and Health Disparities Focused on Early-Stage Life Science Companies
    Breakout Session
    • Diversity‚ Equity and Inclusion
    31C
    Michael Banyas
    Mr. Michael Banyas, Program Manager - National Institute of Minority and Health Disparities
    Corine Farewell
    Dr. Corine Farewell, Director UVM Innovations - University of Vermont
  7. Partnering with CROs and their High-Value Network of Providers to Drive Speed, Cost Effectiveness and Quality in your Clinical Development
    Breakout Session
    • Business Development and Finance
    23BC
    Sponsored by:
    fortrea logo
  8. Promising Advances in Neuroscience: New Molecular Targets and Biomarkers
    Breakout Session
    • Brain Health
    26A
    Hank Safferstein
    Dr. Hank Safferstein, Senior Advisor - UPMC Enterprises
    Susanne Ahmari
    Susanne Ahmari, Assistant Professor, Department of Psychiatry - University of Pittsburgh
    Amit Etkin
    Dr. Amit Etkin, Founder and Chief Executive Officer - Alto Neuroscience
    Maha Radhakrishnan
    Dr. Maha Radhakrishnan, Chief Medical Officer - Biogen
  9. Strategies for Antimicrobial Access in LMICs
    Breakout Session
    • Infectious Disease and Vaccines
    29C
    Jomana Musmar
    Dr. Jomana Musmar, Executive Director of the Presidential Advisory Council for Combating Antibiotic - Resistant Bacteria (PACCARB)
    Monika Schneider
    Dr. Monika Schneider, Director, Global AMR Policy - Shionogi
    Kevin Outterson
    Prof. Kevin Outterson, Executive Director - CARB-X
    Yann Ferrisse
    Mr. Yann Ferrisse, Business Development & Partner Engagement Director - GARDP Foundation
  10. Student Program: An Introduction to the Biotechnology Industry
    Special Program 29AB
3:00 PM – 4:00 PM
(PST)
  1. Breaking the Cycle: Innovations in Addressing Substance Use Disorder
    Breakout Session
    • Brain Health
    26A
    Courtney Miller
    Dr. Courtney Miller, Founder, Myosin Therapeutics; Professor Department of Molecular Medicine, Department of Neuroscience - UF Scripps Biomedical Research
    Joanne Peterson
    Joanne Peterson, Founder and Executive Director - Learn to Cope
    James Hickman
    Dr. James Hickman, Professor of NanoScience, Chemistry, Biomolecular Science, Physics and Electrical Engineering, University of Central Florida; Chief Scientist - Hesperos
  2. Building a More Sustainable Biopharma Innovation Ecosystem
    Breakout Session
    • Environmental Sustainability
    29C
    Rachel Kaufman
    Rachel Kaufman, Head of Global Sustainability - Avantor
    Joydeep Ganguly
    Joydeep Ganguly, Senior Vice President of Corporate Operations, and Chief Sustainability Officer - Gilead Sciences
    Mark Steen
    Mark Steen, VP, Sustainability and Climate Initiatives - Corning
  3. Fireside Chat
    Fireside Chat with Joshua Boger, PhD, Founder and Former CEO of Vertex Pharmaceuticals; Executive Chairman, Alkeus Pharmaceuticals; Chair of Board, CervoMed
    Fireside Chat
    • Business Development and Finance
    25ABC
    Joshua Boger
    Dr. Joshua Boger, Founder and Former CEO of Vertex Pharmaceuticals - Executive Chairman, Alkeus Pharmaceuticals; Chair of Board, CervoMed
  4. From Incubation to Acquisition: The Growth Journey of an Early-Stage Company
    Breakout Session
    • Business Development and Finance
    30ABC
    Sponsored by:
    johnson and johnson
    Melinda Richter
    Melinda Richter, Global Head - Johnson & Johnson
    Matt Lorenzi
    Matt Lorenzi, Vice President - Johnson & Johnson
    Colin Farlow
    Colin Farlow, Co-Founder and CEO - Serotiny
    Eric Moessinger
    Eric Moessinger, Partner - +ND Capital
  5. Getting Personal: How the Evolving U.S. Privacy Legal Landscape Impacts Biomedical Research
    Breakout Session
    • AI and Digital Health
    24BC
    Justin Pine
    Justin Pine, Senior Director - Biotechnology Innovation Organization (BIO)
    Kimberly Gold
    Kimberly Gold, Chief Privacy Officer - Genentech
  6. Microgravity: A Strategic Advantage in R&D
    Breakout Session
    • Next Generation Biotherapeutics
    23BC
    Elizabeth Reynolds
    Ms. Elizabeth Reynolds, Managing Director - Starburst Aerospace
    Kate Rubins
    Kate Rubins, Astronaut - NASA
    Paul Reichert
    Mr. Paul Reichert, Associate Principal Scientist - Merck
    Rob Garmise
    Rob Garmise, Director of Formulations Development, Exploratory Biopharmaceutics - Bristol Myers Squibb
  7. Optimizing the Investability of Your Lead Program: Data-Driven Approaches for Pipeline Prioritization
    Breakout Session
    • Business Development and Finance
    32AB
    Drew Cutshaw
    Dr. Drew Cutshaw, Senior Associate, Medical Officer - Pappas Capital
    Mike Grey
    Mike Grey, Chairman - Plexium
    Susan Lenderts
    Ms. Susan Lenderts, Head of Life Sciences - SAS Institute, INC
    Ben Davis
    Ben Davis, Vice President, Corporate Alliances - IQVIA
  8. Preparing for Platforms: Sponsor and Regulator Perspectives on the Platform Technology Designation (PTD)
    Breakout Session
    • Cell and Gene Therapy and Genome Editing
    31AB
    Dylan Bechtle
    Mr. Dylan Bechtle, US Regulatory Policy Lead - Johnson & Johnson
    Snehal Naik
    Snehal Naik, Head of Regulatory Policy - Spark Therapeutics
    Rob Berlin
    Rob Berlin, Head US Regulatory Policy - GSK
    Anne-Virginie Eggimann
    Anne-Virginie Eggimann, Chief Regulatory Officer - Tessera Therapuetics
    Antonella Lozito
    Antonella Lozito, Executive Director, Regulatory Affairs, Infectious Disease - Moderna
    Nicole Verdun
    Dr. Nicole Verdun, Super Office Director, CBER - FDA
  9. Super Session
    Superconvergence: How the AI, Genetics, and Biotechnology Revolutions Will Transform our Lives, Work, and World
    Super Session
    • Next Generation Biotherapeutics
    28ABCDE
    Jamie Metzl
    Jamie Metzl, Founder and Chair - OneShared.World
  10. The Bad and the Ugly: Unpacking Repercussions of the Medicaid Drug Rebate Program Rule
    Breakout Session
    • Business Development and Finance
    29AB
    Matt Salo
    Matt Salo, CEO - Salo Health Strategies
    Pete Norman
    Pete Norman, Senior Vice President - Alkermes, Inc.
  11. Workforce, Diversity, Equity, and Inclusion at BIO: Presenting New Survey Data and Exploring Partnerships
    Breakout Session
    • Diversity‚ Equity and Inclusion
    31C
    Ted Love
    Dr. Ted Love, Chair - BIO Board of Directors
    Charlotte Jones-Burton
    Charlotte Jones-Burton, Founder - Women of Color in Pharma
    Mark Royal
    Mark Royal, Senior Client Partner - Korn Ferry
    Jane Barry-Moran
    Jane Barry-Moran, Managing Director, Programs & Research - Out Leadership
10:30 AM – 4:10 PM
(PST)
  1. Overcoming Development, Scale Up and Commercial Production Challenges for Novel Modalities
    BioProcess BioProcess Theater
4:15 PM – 5:15 PM
(PST)
  1. Adaptive Reuse: Biomanufacturing Enters A New Age
    Breakout Session
    • Environmental Sustainability
    29C
    Matt Gardner
    Matt Gardner, Board Chairman - California Biomanufacturing Center
    TJ Silvey
    TJ Silvey, Director - Raymond James
    Ella Woger-Nieves
    Ella Woger-Nieves, CEO - Invest Puerto Rico
    Gordon Zagar
    Gordon Zagar, President & Founder - ZCI
    Ann-Stewart Patterson
    Ann-Stewart Patterson, Executive Vice President - CBRE
  2. AI-Generated Invention and the Future of Bio R&D
    Breakout Session
    • Intellectual Property
    26B
    Hans Sauer
    Hans Sauer, Deputy General Counsel, VP for IP - Biotechnology Innovation Organization (BIO)
    Ryan Abbott
    Prof. Ryan Abbott, Partner - Brown, Neri, Smith & Khan, LLP
    Andrei Iancu
    Mr. Andrei Iancu, Partner - Sullivan & Cromwell LLP
    Sarah Korman
    Ms. Sarah Korman, General Counsel - Isomorphic Labs
  3. Becoming an Early Innovation Partner of Choice
    Breakout Session
    • Business Development and Finance
    29AB
    David Kane
    David Kane, Managing Partner - Arc Bio Communications
    Helena Chaye
    Helena Chaye, CEO - KaliVir
    Peter Sandor
    Peter Sandor, Senior Vice President, Primary Focus Lead, Primary Focus Immuno-oncology - Astellas Pharma
    Olga Granaturova
    Olga Granaturova, CEO - PrivBio
    Anna Chen
    Anna Chen, Principal - Frazier Life Sciences
  4. Best Practices for Managing Your Biotech’s Ca$hflow
    Breakout Session
    • Business Development and Finance
    32AB
    Joel Papernik
    Mr. Joel Papernik, Member - Mintz
    Barbara Wood
    Ms. Barbara Wood, Executive Vice President, General Counsel and Corporate Secretary - Sellas Life Sciences
    Robert Van Nostrand
    Robert Van Nostrand, Board of Directors Member - Intra-Cellular Therapies
    Heidi Henson
    Ms. Heidi Henson, Director - Lisata Therapeutics
    Robert Easton
    Mr. Robert Easton - Eastern Strategy, LLC
  5. Challenging Biotech’s One-Track Mind When it Comes to Neuropsychiatric Drug Innovation
    Breakout Session
    • Brain Health
    26A
    Heather McKenzie
    Ms. Heather McKenzie, Senior Editor - BioSpace
    Laxminarayan Bhat
    Dr. Laxminarayan Bhat, CEO - Reviva Pharmaceuticals Inc
    Amit Etkin
    Dr. Amit Etkin, Founder and Chief Executive Officer - Alto Neuroscience
    Daniel Karlin
    Daniel Karlin, Chief Medical Officer - Mind Medicine (MindMed)
    David Benshoof Klein
    David Benshoof Klein, Co-Founder and CEO - Click Therapeutics
  6. Exploring the Future of Gene Delivery: A Conversation on the Direction for Next-Generation Vectors
    Breakout Session
    • Cell and Gene Therapy and Genome Editing
    31AB
    Ola Tuvesson
    Mr. Ola Tuvesson, Chief Technology Officer - NorthX Biologics
    Johan Rockberg
    Prof. Johan Rockberg, Professor at the Royal Institute of Technology and Director of GeneNova - Royal Institute of Technology
    Peter de Haan
    Dr. Peter de Haan, Founder and Chief Scientific Officer - Amarna Therapeutics BV
    Amy Walker
    Dr. Amy Walker, Vice President of Research and Business Development - 4BaseBio PLC
  7. Exploring the Uncharted: Rare Diseases, Unintended Consequences of the Inflation Reduction Act, and Demonstrating the Value of These Therapies
    Breakout Session
    • Orphan and Rare Disease
    30DE
    Sponsored by:
    alexion logo
    John Murphy
    John Murphy, Chief Policy Officer - Biotechnology Innovation Organization (BIO)
  8. Future of Biopharma Innovation: Unleashing the Potential of Emerging Therapeutic Modalities in Oncology and Beyond
    Breakout Session
    • Next Generation Biotherapeutics
    23BC
    Romain Bonnot
    Romain Bonnot, Principal - ZS Associates
    Jesper Haaning
    Jesper Haaning, Head of Development External Innovation - Novo Nordisk
    Lucas Donigian
    Lucas Donigian, Executive Director, Business Development - Zymeworks Inc.
    Malik Kaman
    Malik Kaman, Principal - ZS Associates
  9. Highlighting the Power of Patient Organizations: Exploring Initiatives That Drive Equitable Impact for Patients and Communities
    Breakout Session
    • Diversity‚ Equity and Inclusion
    31C
    Deepa Dahal
    Ms. Deepa Dahal, Co-founder and Partner - DKI Health. LLC
    Mary Stutts
    Ms. Mary Stutts, Chief Executive Officer - Healthcare Businesswomen's Association
    Joseph Nadglowski
    Mr. Joseph Nadglowski, President and Chief Executive Officer - Obesity Action Coalition
    Christine Verini
    Ms. Christine Verini, CEO - CancerCare
    Sonali Chopra
    Ms. Sonali Chopra, Executive Director, Patient Advocacy Relations - Genentech a Member of the Roche Group
  10. The Future of Immunology: Path to Precision Medicine
    Breakout Session
    • Diagnostics and Personalized Medicine
    24BC
    Sponsored by:

    merck logo

    Max Bayer
    Max Bayer, Staff Reporter - Fierce Biotech
    Aileen Lorenzo Pangan
    Aileen Lorenzo Pangan, Vice President & Therapeutic Area Head - Merck
    Cynthia Bens
    Cynthia Bens, Senior Vice President - Personalized Medicine Coalition
  11. Fireside Chat
    Thinking Outside the Lab: Lessons from Nobel Laureate Carolyn Bertozzi, PhD, on Building Blockbuster Biotech Companies
    Fireside Chat 25ABC
    Jenny Rooke
    Jenny Rooke, Founder and Managing Director - Genoa Venture
    Carolyn Bertozzi
    Carolyn Bertozzi, Professor of Chemistry - Stanford University
11:00 AM – 12:00 PM
(PST)
  1. Achieving Commercial Success Through the National Institutes of Health's Intramural Research Program
    Breakout Session
    • Business Development and Finance
    32AB
    Michael Salgaller
    Dr. Michael Salgaller, Supervisory Specialist, National Cancer Institute Tech Transfer Center - National Institutes of Health (NIH)
    Mark Rohrbaugh
    Dr. Mark Rohrbaugh, Special Advisor for NIH Technology Transfer - National Institutes of Health (NIH)
    Margaret Anderson
    Ms. Margaret Anderson, Managing Director - Deloitte Consulting LLP
    Jeffery Alexander
    Dr. Jeffery Alexander, Director, Innovation Policy - RTI International
    Melissa Bonner
    Melissa Bonner, Chief Scientific Officer - Nvelop Therapeutics
  2. Biotech Partnering in Stormy Seas: Key Insights on Charting a Course to Successful Deal-Making through a Choppy Market
    Breakout Session
    • Business Development and Finance
    29AB
    Kate Hillier
    Kate Hillier, Partner - Cooley LLP
    Barbara Kosacz
    Mrs. Barbara Kosacz, COO and General Counsel - Kronos Bio
    Brian Cuneo
    Brian Cuneo, Senior Partner - ARCH Venture Partners
    Joseph Baroldi
    Mr. Joseph Baroldi, Executive Vice President, Chief Business Officer Ionis Pharmaceuticals - Ionis Pharmaceuticals
    Stacy Feld
    Stacy Feld, Regional Head - Johnson & Johnson Innovation
  3. Breaking the Rare Disease Deadlock through Multi-Stakeholder Collaboration
    Breakout Session
    • Orphan and Rare Disease
    26A
    Niklas Blomberg
    Dr. Niklas Blomberg, Executive Director - Innovative Health Initiative
    Annette Bakker
    Dr. Annette Bakker, President - Children's Tumor Foundation
    Klaus Romero
    Dr. Klaus Romero, Chief Executive Officer, Chief Science Officer - Critical Path Institute
    Deborah Requesens
    Dr. Deborah Requesens, Director, JumpStart Program - Orphan Disease Center, Perelman School of Medicine, University of Pennsylvania
    Claire Skentelbery
    Dr. Claire Skentelbery, Director General - EuropaBio
  4. How to De-Risk Drug Development from the Earliest Stages
    Breakout Session
    • Business Development and Finance
    23BC
  5. Open Innovation in Life Sciences, Decades of Experiences, Time to Regroup!
    Breakout Session
    • Translational Research
    31AB
    Junjun Gao
    Junjun Gao, Sr director BD&L - Bayer
    Karen Chandross
    Karen Chandross, Head, Strategic Initiatives and Scientific Relations N.A. • R&D North America - Sanofi
    Florian Montel
    Florian Montel, Head of Open Sciences - Boehringher Ingelheim
    Pamela Hill
    Pamela Hill, Sr. Director, Head of Open Innovation Program - Astra Zeneca
  6. Post-Guidance Opportunities and Challenges with Prescription Drug Use-Related Software (PDURS)
    Breakout Session
    • AI and Digital Health
    24BC
    Rob Berlin
    Rob Berlin, Head US Regulatory Policy - GSK
    Eva Temkin
    Eva Temkin, Partner - King & Spalding
    Renee Beaver
    Renee Beaver, Director, Commercial Counsel - Otsuka Pharmaceutical
  7. Rising to the Challenge of Science Regulation: Ensuring Public Policy Keeps Pace with Innovation Ecosystem
    Breakout Session
    • Environmental Sustainability
    29C
    Alex Menotti
    Alex Menotti, Vice President, Government Affairs, Policy, and Sustainability - LanzaJet
  8. Running a Biotech Company: Perspectives from Women Powerbrokers
    Breakout Session
    • Diversity‚ Equity and Inclusion
    31C
    Joshua Fox
    Mr. Joshua Fox, Member - Mintz
    Anna Turetsky
    Ms. Anna Turetsky, Principal, Venture Investments - The Mark Foundation for Cancer Research
    Laura Indolfi
    Laura Indolfi, Chief Executive Officer and Co-Founder - PanTher Therapeutics
    Sabrina Johnson
    Ms. Sabrina Johnson, President and CEO - Daré Bioscience, Inc.
  9. Using AI/ML for Identification and Optimization of Therapeutic Molecules
    Breakout Session
    • AI and Digital Health
    30ABC
    Sponsored by:
    johnson and johnson
    Michal Preminger
    Michal Preminger, Regional Head - Johnson & Johnson Innovation East North America
12:15 PM – 1:30 PM
(PST)
  1. Super Session
    Fireside Chat with David Moore, Executive Vice President, Corporate Development, Novo Nordisk
    Super Session
    • Business Development and Finance
    25ABC
    David Moore
    David Moore, Executive Vice President, Corporate Development - Novo Nordisk
1:45 PM – 2:45 PM
(PST)
  1. Advancing Innovation: Best Practices for University-Industry Collaboration
    Breakout Session
    • Translational Research
    31AB
    Ed Pagani
    Dr. Ed Pagani, Executive Director, Office for External Partnerships, and Assistant VP, External Partnerships - Duke University
    Caroline Lowenthal
    Ms. Caroline Lowenthal, Alliance Manager - MIT
    Tari Suprapto
    Dr. Tari Suprapto, Director, Search & Evaluation (Western US & Canada) - Novo Nordisk
    Sunita Rajdev
    Sunita Rajdev, Director - Licensing and Strategic Alliances, Life Sciences - Stanford University
    Doug Krafte
    Doug Krafte, Site Head – Durham, North Carolina, and Sr. Vice President, Ion Channels/Transporters - OmniAb
  2. Biotech Innovations for Pet Health
    Breakout Session
    • Environmental Sustainability
    29C
    Tammie Wahaus
    Tammie Wahaus, CEO - Elias Animal Health LLC
    Dylan Balsz
    Dylan Balsz, CEO - Anivive Lifesciences
  3. Building Winning Presentations and Using Emotional Intelligence as a Tool for Success
    Breakout Session
    • Business Development and Finance
    32AB
    Elise Simard
    Mrs. Elise Simard, Speaker Trainer/Coach - LaVoieHealthScience
    Donna LaVoie
    Mrs. Donna LaVoie, Founder & CEO - LaVoieHealthScience
  4. Cell Therapy Primer
    Breakout Session
    • Cell and Gene Therapy and Genome Editing
    23BC
    Kevin Curran
    Dr. Kevin Curran, Scientific Advisor and Instructor - BioTech Primer
  5. Changing Clinical Trial Designs in the IRA Environment and Impacts on Stakeholders in Rare and Ultra-Rare Disease Space
    Breakout Session
    • Orphan and Rare Disease
    26A
    Mariia Salova
    Ms. Mariia Salova, Consultant II - Avalere
    Amy House
    Amy House, Head of Portfolio Strategy - Beacon Therapeutics
    Primal Kaur
    Primal Kaur, Vice President, Global Development - Amgen
    Matthew Klein
    Matthew Klein, Chief Executive Officer and President - PTC Therapeutics
    Mike Stodghill
    Mike Stodghill, Patient Perspective - Mackenzie's Mission
  6. Diversifying the Talent Pipeline: Industry-Recognized Curriculum for a Skilled Workforce
    Breakout Session
    • Diversity‚ Equity and Inclusion
    31C
    Vicki Brannock
    Ms. Vicki Brannock, Senior Director Workforce Strategy & Innovation - Biocom California Institute
    Scott Eaker
    Mr. Scott Eaker, Chief Operations Officer - Prolacta
    Willie Zuniga
    Mr. Willie Zuniga, Retired, Former President and Site Head - Grifols Biologicals
    Judith Velasco
    Mrs. Judith Velasco, Executive Director - Verdugo Workforce Development Board
    Linnea Fletcher
    Dr. Linnea Fletcher, Executive Director - InnovATEBIO, National Biotechnology Center
  7. New Tools, New Times: Chemical and Structural AI for Drug Discovery
    Breakout Session
    • AI and Digital Health
    24BC
    Ayman AlAbdallah
    Mr. Ayman AlAbdallah, Partner - Mubadala Capital
    Lee Cronin
    Prof Lee Cronin, Founder and Chief Executive Officer - Chemify
    Raphael Townshend
    Mr. Raphael Townshend, Founder & CEO - Atomic AI
    Tom Miller
    Tom Miller, CEO and co-founder - Iambic Therapeutics
  8. Student Program: Entry into Early Careers in Biotechnology
    Special Program 29AB
  9. The Oncology Endgame: Assemble and Shine with AI and Precision Medicine, or Lose.
    Breakout Session
    • Oncology
    26B
    Karim Budhwani
    Dr. Karim Budhwani, CEO-Scientist - CerFlux
    Tahera Kan
    Tahera Kan, Vice President, Head of Precision Medicine - Johnson & Johnson
    Sandeep Menon
    Dr. Sandeep Menon, Chief Scientific Officer, AI Digital Sciences and SVP, Head of Early Clinical Development - Pfizer
    Maggie Scully
    Dr. Maggie Scully, Partnership Development Director - Frederick National Laboratory for Cancer Research
3:00 PM – 4:00 PM
(PST)
  1. AI's Impact on Oncology Cancer Drug Development
    Breakout Session
    • Oncology
    26B
    Wyatt McDonnell
    Dr. Wyatt McDonnell, CEO & Co-founder - Infinimmune
    Jakob Dupont
    Jakob Dupont, Executive Partner - Sofinnova Investments
    Kamni Vijay
    Kamni Vijay, CEO - Enable Medicine
    Andrei Georgescu
    Andrei Georgescu, CEO & Founder - Vivodyne
    Daniel Silva Manzano
    Mr. Daniel Silva Manzano, CEO & Co-Founder - Monod Bio
    Abe Heifets
    Abe Heifets, CEO & Co-Founder - Atomwise
  2. Blueprints for Biotech: Designing Deals that Deliver
    Breakout Session
    • Business Development and Finance
    32AB
    Matthew Hudes
    Mr. Matthew Hudes, Founder & CEO - BdlBiologx
    Christopher Walsh
    Dr. Christopher Walsh, Senior Vice President, General Counsel - Denali Therapeutics Inc.
    Bryan Glaser
    Dr. Bryan Glaser, Senior Vice President, Business Development - Invenra Inc.
    Saira Ramasastry
    Ms. Saira Ramasastry, Partner - LSA / Sanacor
    Grace Han McMahon
    Ms. Grace Han McMahon, Associate Vice President and Head of Transactions for Merck’s BD&L Pacific Innovation Hub - Merck
  3. Developing Successful DEI Programs for Life Sciences Companies
    Breakout Session
    • Diversity‚ Equity and Inclusion
    31C
    Marredia Crawford
    Ms. Marredia Crawford, Chief Inclusion, Diversity and Equity Officer - Baker McKenzie
    Nicole Stovall
    Nicole Stovall, AVP, Diversity Strategy and Innovation - Merck
    Alessandra Ravetti
    Alessandra Ravetti, Senior Vice President, Associate General Counsel - Regeneron Pharmaceuticals
  4. Driving Biotech Success: What Every CEO Needs from Her C-Level Team
    Breakout Session
    • Business Development and Finance
    29AB
    Mary Haak-Frendscho
    Dr. Mary Haak-Frendscho, President and CEO - Spotlight Therapeutics
    Karen Boezi
    Ms. Karen Boezi, Chief Operating Officer - Thirona Biosciences
    Seema Kantak
    Dr. Seema Kantak, Senior Vice President, Biotherapeutics - Exelixis
    Nikita Jaipuria
    Ms. Nikita Jaipuria, Business Development, Senior Manager, Transactions - Amgen
    Cindy Dunkle
    Ms. Cindy Dunkle, Chief People Officer - Denali
  5. Organizing to Derisk Academic Assets
    Breakout Session
    • Translational Research
    31AB
    Michelle Hoffmann
    Dr. Michelle Hoffmann, Executive Director - Chicago Biomedical Consortium
    Lisa Dhar
    Dr. Lisa Dhar, Associate Vice President for Innovation and New Ventures - Northwestern Innovation and New Ventures Office
    Aleks Baranczak
    Dr. Aleks Baranczak, Chief Program Officer - Blackbird Labs
    Craig Linsdley
    Dr. Craig Linsdley, University Professor of Pharmacology William K. Warren, Jr. Chair in Medicine - Vaderbilt University
    Eric Schiffhauer
    Dr. Eric Schiffhauer, Director of Outreach - Deerfield Management
    Jonathan Young
    Dr. Jonathan Young, Head of WARF Therapeutics - Wisconsin Alumni Research Foundation (WARF)
  6. PDABs and the IRA: The Impact of Federal Legislation on State-Level Prescription Pricing Practices
    Breakout Session
    • Value‚ Patient Access and Reimbursement
    23BC
    Elizabeth (Liz) Helms
    Elizabeth (Liz) Helms, President and CEO - California Chronic Care Coalition
    John O’Brien
    Dr. John O’Brien, President and CEO - National Pharmaceutical Council
    Christopher (Brett) Johnson
    Christopher (Brett) Johnson, Director, State Government Affairs - Amgen
    Tiffany Westrich-Robertson
    Tiffany Westrich-Robertson, Chief Executive Officer and Co-Founder - AiArthritis
  7. The Promise of Individualized Treatment for Cancer: How Individualized Neoantigen Therapy (INT) Will Change Oncology
    Breakout Session
    • Oncology
    26A
    Sponsored by:

    merck logo

    Scot Ebbinghaus
    Scot Ebbinghaus, Vice President - Merck
  8. Thriving in the Age of Digital Insecurity: New Reporting Obligations and Cyber Resilience for Life Sciences Companies
    Breakout Session
    • AI and Digital Health
    24BC
    Justine Phillips
    Ms. Justine Phillips, Partner - Baker McKenzie
    Todd Hemmen
    Todd Hemmen, Chief, Cyber Technical Analytics and Operations Section, Cyber Division - US Department of Justice, Federal Bureau of Investigation
    Nick Arico
    Nick Arico, Supervisory Special Agent - US Department of Justice, Federal Bureau of Investigation
    Lisel Newton
    Lisel Newton, Senior Director, Information Security, Risk & Compliance - Gossamer Bio
    Anne Blake-Dreher
    Anne Blake-Dreher, Vice President and Assistant General Counsel - Perrigo
  9. Vaccinating Against Mistrust and Misinformation During an Infodemic
    Breakout Session
    • Infectious Disease and Vaccines
    30DE
    Silvia Taylor
    Ms. Silvia Taylor, Executive Vice President, Chief Corporate Affairs & Advocacy Officer - Novavax, Inc.
    Reed Tuckson
    Dr. Reed Tuckson, Managing Director / Co-Founder - Tuckson Health Connections, LLC / Black Coaliition Against COVID-19
    Pedro Martinez
    Mr. Pedro Martinez, Director, Health - UnidosUS
    Sue Peschin
    Sue Peschin, President and CEO - Alliance for Aging Research
    Joe Smyser
    Joe Smyser, CEO - The Public Good Projects (PGP)
10:30 AM – 4:10 PM
(PST)
  1. Incorporating New Technologies in Development and Production, Regulatory Landscapes, and Agile Manufacturing
    BioProcess BioProcess Theater
4:15 PM – 5:15 PM
(PST)
  1. Adult Vaccination: New Vaccines, New Opportunities to Protect Public Health
    Breakout Session
    • Infectious Disease and Vaccines
    32AB
    Sponsored by:

    merck logo

    Jannie Oosthuizen
    Jannie Oosthuizen, President - Merck
  2. Co-opting Biological Processes to Drug Cancer and Other Diseases
    Breakout Session
    • Oncology
    26B
    Mariana Mihalusova
    Mariana Mihalusova, Investor - Venrock
    Larry Hamann
    Dr. Larry Hamann, Co-founder/CEO - Interdict Bio
    Aetna Wun Trombley
    Aetna Wun Trombley, CEO - Lycia
    Bernd Boidol
    Mr. Bernd Boidol, CEO - Proxygen
    Brian Fiske
    Dr. Brian Fiske, Co-founder/CSO - Mythic Therapeutics
  3. Enhancing Clinical Trial Diversity Through a Patient-Centric, Data Driven Approach
    Breakout Session
    • Diversity‚ Equity and Inclusion
    31C
    Trevan Locke
    Dr. Trevan Locke, Assistant Research Director - Duke-Margolis Institute for Health Policy
    Megan Fesinmeyer
    Megan Fesinmeyer, Observational Research Senior Manager - Amgen
    Carla Rodriguez-Watson
    Carla Rodriguez-Watson, Director of Research
    Darryl Sleep
    Darryl Sleep, Head, Global Public Health - Amgen
  4. Evolution of the IRA: A New-Year, a Potential New Administration, Yet Tackling the Same Access and Affordability Challenges
    Breakout Session
    • Value‚ Patient Access and Reimbursement
    23BC
    Stephen Morales
    Mr. Stephen Morales, Senior Principal - Blue Fin Group, An IntegriChain Company
    Gerry Gleeson
    Gerry Gleeson, Head of US Market Access - Sanofi
    Bill Sarraille
    Bill Sarraille, Retired Senior Partner - Sidley Austin LLC
    Albert Thigpen
    Albert Thigpen, Operating Advisor - Nautic Partners
    Bill Roth
    Bill Roth, Founding Partner - Blue Fin Group
  5. Fireside Chat
    Fireside Chat with Nina Kjellson, General Partner, Canaan Partners
    Fireside Chat
    • Business Development and Finance
    25ABC
    Nina Kjellson
    Nina Kjellson, General Partner - Canaan Partners
  6. IPOs Are Starting to Come Back: Are You Ready?
    Breakout Session
    • Business Development and Finance
    29AB
    Rich Ramko
    Mr. Rich Ramko, Partner, US Biotech Leader - EY (Ernst & Young)
    Neha Krishnamohan
    Neha Krishnamohan, Former Chief Financial Officer and Executive Vice President of Corporate Development - Kinnate Biopharma, Inc.
    Steven Spector
    Steven Spector, Executive Vice President, Head of Business Development and General Counsel - Longboard Pharma
    Brad Wolff
    Brad Wolff, Senior Managing Director |Global Advisory | Strategic Advisory | Mergers and Acquisition - Evercore
  7. Moving from the Lab Bench to the Biotech C-Suite: Insights on Running a Founder-Led Biotech
    Breakout Session
    • Translational Research
    31AB
    Max Bayer
    Max Bayer, Staff Reporter - Fierce Biotech
    Kevin Parker
    Kevin Parker, CEO and Co-founder - Cartography Biosciences
    Jordi Mata-Fink
    Mr. Jordi Mata-Fink, CEO and Co-founder - Gate Bioscience
    Trevor Martin
    Mr. Trevor Martin, CEO and Co-founder - Mammoth Biosciences
    Kira Poskanzer
    Dr. Kira Poskanzer, Founder-in-Residence - Arcadia Science
    Heather Bowerman
    Ms. Heather Bowerman, CEO & Founder - DotLab
  8. Overcoming Systemic Data Bias via AI and Digital Health Tools: Perspectives from Providers, Pharma and Innovators
    Breakout Session
    • AI and Digital Health
    24BC
    Alexis Bortniker
    Alexis Bortniker, Partner - Cooley LLP
  9. Policy and Practice Strategies to Address the Clinical Practice Gaps Affecting the Implementation of Precision Oncology
    Breakout Session
    • Diagnostics and Personalized Medicine
    26A
    Daryl Pritchard
    Dr. Daryl Pritchard, Senior Vice President - Personalized Medicine Coalition
    Jonathan Katchmore
    Jonathan Katchmore, Vice President of Commercial Diagnostic Strategy - Eli Lilly
    Peter Hulick
    Dr. Peter Hulick, Medical Director, Center for Personalized Medicine - NorthShore / Endeavor Health
    Robert Dumanois
    Mr. Robert Dumanois, Director, Reimbursement Strategy - Thermo Fisher Scientific
    Wendy Levin
    Wendy Levin, Chief Medical Officer - Biofidelity
9:00 AM – 10:00 AM
(PST)
  1. Achieving the WHO Cervical Cancer Elimination Targets: The Value of Innovation in Achieving Pivotal Public Health Goals
    Breakout Session
    • Infectious Disease and Vaccines
    23BC
    Sponsored by:

    merck logo

  2. Exploring Deal-Making Options for Your Portfolio of Assets
    Breakout Session
    • Business Development and Finance
    29AB
    Nisha Nanda
    Dr. Nisha Nanda, Group Vice President, Business Development - Eli Lilly
    Adam Rosenthal
    Dr. Adam Rosenthal, CEO and Founder - Star Therapeutics
    Bassil Dahiyat
    Dr. Bassil Dahiyat, President and Chief Executive Officer - Xencor, Inc.
    James Mutamba
    Dr. James Mutamba, Chief Business Officer - Arrakis Therapeutics
    Caroline Stark Beer
    Caroline Stark Beer, Chief Business Officer - Jnana Therapeutics
  3. Immune System Biomarkers: Can Our Antibodies Predict How We Will React to Disease and Immunotherapy?
    Breakout Session
    • Diagnostics and Personalized Medicine
    26A
    Moira Gunn
    Dr. Moira Gunn, Radio Host - BiotechNation
    Martin Gouldstone
    Martin Gouldstone, Chief Executive Officer - Oncimmune
    G. Scott Chandler
    Dr. G. Scott Chandler, Global Head, Personalized Health Care (PHC) Safety - F. Hoffmann-La Roche
    Ashley Orillion
    Dr. Ashley Orillion, Principle Scientist, AAb PAS Biomarker Platform Development Lead - Janssen Immunology
    Justina Fert-Bober
    Dr. Justina Fert-Bober, Project Scientist - Cedars Sinai Medical Center
  4. New Approaches in Radiopharmaceuticals
    Breakout Session
    • Oncology
    31AB
    Karen Tkach Tuzman
    Karen Tkach Tuzman, Director of Biopharma Intelligence, Head of Discovery and Preclinical Research - BioCentury
    Dave Greenwald
    Dr. Dave Greenwald, CEO of Aviko Radiopharmaceuticals and vice president, business development - Deerfield Management
    Ken Song
    Ken Song, former CEO - RayzeBio
    Suji Jeong
    Dr. Suji Jeong, Founding Partner - The SJR Group
    Jeevan Virk
    Jeevan Virk, Therapeutic Area Strategy Head - Novartis
  5. Revolutionizing Clinical Trials: Patient Registries, Wearable Tech, and Video Capture
    Breakout Session
    • Clinical Trials Innovations
    26B
    Klaus Romero
    Dr. Klaus Romero, Chief Executive Officer, Chief Science Officer - Critical Path Institute
    Allison Moore
    Mrs. Allison Moore, Founder/CEO - Hereditary Neuropathy Foundation
    Tina Duong
    Dr. Tina Duong, Dir, Clinical Outcomes R & D Stanford University - Stanford University
    Jason Colquitt
    Jason Colquitt, CEO - Across Healthcare
    Michelle Campbell
    Dr. Michelle Campbell, Associate Director, Stakeholder Engagement & Clinical Outcomes, Office of Neuroscience - FDA
  6. Surviving Turbulence: Extending Runway and Creating Value in Healthcare and Biotech
    Breakout Session
    • Business Development and Finance
    32AB
    Gwendolyn Wu
    Gwendolyn Wu, Reporter - BioPharma Dive
    Cristina Ghenoiu
    Cristina Ghenoiu, Investor - Mubadala Capital
    Nate Chang
    Nate Chang, Operating Partner, Life Sciences - Playground Global
    Rakhshita Dhar
    Rakhshita Dhar, Senior Director of Venture Investments Health - Leaps by Bayer
    Andy Seid
    Andy Seid, Partner - Bioluminescence Ventures
  7. The US Supreme Court and the End of Scientific Deference?
    Breakout Session
    • Regulatory Innovation
    31C
    Stacy Amin
    Stacy Amin, Former FDA Chief Counsel - Morrison Foerster
    Rob MacRae
    Rob MacRae, General Counsel - GSK
    Karen Day
    Karen Day, Senior Corporate Counsel - Pfizer
    Sarah Isgur
    Sarah Isgur, ABC News Analyst and Host, Advisory Opinions Podcast - ABC News
    Jim Stansel
    Jim Stansel, General Counsel - PhRMA
    Julie Lovas
    Julie Lovas, Deputy General Counsel - Department of Health and Human Services
  8. What’s Nex-T: Innovator Roundtable on T Cell Therapies in Oncology
    Breakout Session
    • Oncology
    24BC
    Angus Liu
    Angus Liu, Senior Writer - Fierce Pharma / Fierce Biotech
    Keir Loiacono
    Keir Loiacono, Chief Executive Officer - BlueSphere Bio
    Dan Passeri
    Dan Passeri, Chief Executive Officer - Cue Biopharma
    David Fontana
    David Fontana, Chief Operating and Chief Business Officer - Umoja Biopharma
10:15 AM – 11:15 AM
(PST)
  1. Advancing the Global Regulatory Decision-Making with Public Private Partnerships
    Breakout Session
    • Regulatory Innovation
    31C
    Susan Winckler
    Ms. Susan Winckler, CEO - Reagan-Udall Foundation for the FDA
    Klaus Romero
    Dr. Klaus Romero, Chief Executive Officer, Chief Science Officer - Critical Path Institute
    Adora Ndu
    Adora Ndu, Chief Regulatory Affairs Officer - BridgeBio
    Carlos Garner
    Carlos Garner, Senior Vice President, Global Regulatory Affairs - Eli Lilly
  2. Approaching the Tipping Point: The Emergence of Allogeneic Cell Therapy for Oncology
    Breakout Session
    • Oncology
    31AB
    George Eastwood
    Mr. George Eastwood, Board Chair/Interim Executive Director - The Emily Whitehead Foundation
    Cokey Nguyen
    Dr. Cokey Nguyen, Chief Scientific and Technical Officer - Atara Biosciences
    Abigail Jenkins
    Ms. Abigail Jenkins, President & CEO - Gamida Cell
    P.K. Morrow
    Dr. P.K. Morrow, Senior Vice President and Head of Oncology Therapeutic Area Unit - Takeda
    Kristin Yarema
    Dr. Kristin Yarema, President & CEO - Poseida Therapeutics
  3. Changing the Game: Innovation to End HIV
    Breakout Session
    • Infectious Disease and Vaccines
    29C
    Cecilia Chung
    Cecilia Chung, Senior Director, Strategic Initiatives and Evaluation - Transgender Law Center
    Micheal Ighodaro
    Micheal Ighodaro, Co-Executive Director - Prevention Access Campaign
    Jenelle Krishnamoorthy
    Jenelle Krishnamoorthy, Vice President, Head of Global Public Policy and International Affairs - Merck
    Ji Ma
    Ji Ma, Head of Discovery - Brii Biosciences
    Sandra Thurman
    Sandra Thurman, Senior Advisor to the Division of Global HIV and Tuberculosis - CDC
  4. Competing as a Diagnostic Company in the Current Funding Environment: New Funding Models
    Breakout Session
    • Diagnostics and Personalized Medicine
    26A
    Bernard Peperstraete
    Dr. Bernard Peperstraete, CEO and Co-Founder - AcuamarkDx
    Magali Haas
    Dr. Magali Haas, CEO and President - Cohen Veterans Bioscience
  5. Inside the VC Playbook: Overcoming Obstacles in Challenging Markets for Success
    Breakout Session
    • Business Development and Finance
    32AB
    Kimberly Ha
    Ms. Kimberly Ha, Founder - KKH Advisors
    Troy Ignelzi
    Troy Ignelzi, Executive Advisor - Sofinnova Investments
    Andrew Lam
    Andrew Lam, Head of Biotech Investment - Ally Bridge Group
    Enoch Kariuki
    Enoch Kariuki, President - Endeavor Biomedicines
    Sheila Gujrathi
    Sheila Gujrathi, Biotech Executive and Entrepreneur
    Carol Gallagher
    Carol Gallagher, Independent Director
  6. Is Oncology Still a Hot Spot for Biopharma Deals?
    Breakout Session
    • Oncology
    24BC
    Ashwin Singhania
    Ashwin Singhania, Partner/Principal - EY (Ernst & Young)
    Ben Hickey
    Ben Hickey, President - RayzeBio
  7. Partnering with ARPA-H: New Opportunities and Best Practices for Engaging a Transformative R&D Funder
    Breakout Session
    • Business Development and Finance
    29AB
    Susan Monarez
    Dr. Susan Monarez, Deputy Director - Advanced Research Projects Agency for Health (ARPA-H)
    Jason Roos
    Dr. Jason Roos, Director, Scalable Solutions - Advanced Research Projects Agency for Health (ARPA-H)
    Wade Shen
    Wade Shen, Director, Proactive Health - Advanced Research Projects Agency for Health (ARPA-H)
  8. Regulators & DTRA Enabling DCTs
    Breakout Session
    • Clinical Trials Innovations
    26B
    Amir Kalali
    Dr. Amir Kalali, Co Chair - DTRA
    Jane Myles
    Jane Myles, Program Director - DTRA
    Rasika Kalamegham
    Rasika Kalamegham, Head US Regulatory Policy - Genentech
    Steffen Thirstrup
    Dr. Steffen Thirstrup, Chief Medical Officer - European Medicines Agency (EMA)

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS

Loading

Search